Letters to Officials
CAGW Sends "Pharmaceutical Price Controls are Bad Medicine" to Congress
Drug price controls will threaten medical innovation, reduce research and development, and cost American jobs.
CCAGW Joins Coalition Opposing Drug Price Controls in H.R. 5376, the Build Back Better Act
Price controls and inflation penalties threaten medial innvoation, reduce research and innovation, and threaten American jobs.
CCAGW Joins Coalition Opposing Changes to Real Estate Taxes
Several proposals put forth this Congress have the potential to make operating and passing on a family business more difficult.
CCAGW Urges House to Oppose H.R. 5376
H.R. 5376 is a massive tax and spending bill that would vastly expand the size and scope of government and bankrupt taxpayers.
CCAGW Urges House to Oppose H.R. 3684
H.R. 3684 is a massive spending bill disguised as an infrastructure bill and the costs far outweigh the benefits.
CCAGW Joins Coalition Encouraging WHO to Adopt Tobacco Harm Reduction Policies
The U.S. delegation to the WHO should advocate harm reduction policies as part of an overall tobacco control strategy.
CCAGW Urges Senate Judiciary Committee to Oppose the American Choice and Innovation Online Act
The American Choice and Innovation Online Act would dramatically undermine and thwart the consumer welfare standard.
CCAGW Urges Senate Judiciary Committee to Oppose S. 2428
S. 2428 would undermine and weaken the False Claims Act.
CAGW Sends 2021 Prime Cuts to Congress
The 2021 Prime Cuts Report is not only required reading, it is also a roadmap for the bold action needed to restore fiscal sanity.
CAGW Sends "Government-Run Healthcare Will Harm Patients and Eliminate Consumer Choice" to Congress
The best solution for healthcare reform is a free-market system that ensures individuals make their own choices.
CCAGW Urges House to Oppose H.R. 3684
H.R. 3684 is a massive spending bill disguised as an infrastructure bill and the risks and costs far outweigh ant benefits.
CCAGW Urges House Judiciary Committee to Oppose H.R. 2873
The language in H.R. 2873 is too far-reaching and will harm legitimate pharmaceutical innovation.
